Key result
Elevated RBP4 predicts higher 6-month MACE risk in symptomatic PAD patients undergoing endovascular revascularization.
Why the study?
RBP4 has an established role in atherosclerosis and adiponectin has anti-inflammatory properties, but their association with symptomatic PAD and prognostic role in MACE required investigation.
Do baseline serum RBP4 and adiponectin levels predict the presence of PAD and the 6-month incidence of MACE in patients undergoing lower limb endovascular revascularization?
Cohort (n=256)
Yes
Do baseline serum RBP4 and adiponectin levels predict the presence of PAD and the 6-month incidence of MACE in patients undergoing lower limb endovascular revascularization?
Elevated baseline serum RBP4 levels are independently associated with the presence of PAD and predict a higher 6-month incidence of MACE following lower limb endovascular revascularization.
Answers are grounded in this paper and cite their sources.
RBP4 may refine short-term MACE risk stratification after PAD revascularization; hypothesis-generating and should not yet change practice.
BACKGROUND: RBP4 is an adipokine with an established role in atherosclerosis, while adiponectin has unique anti-inflammatory properties. We investigated the association of RBP4 and adiponectin with the presence of symptomatic peripheral artery disease (PAD) and their possible prognostic role in major adverse cardiovascular events (MACE). METHODS: We enrolled 168 consecutive patients with symptomatic, established PAD, requiring revascularization by endovascular means of any or both of their lower limbs. 88 age- and sex-matched subjects with less than 2 classical cardiovascular risk factors served as controls. Clinical parameters, glycemic and lipid profile, RBP4 and adiponectin levels were assayed. The occurrence of MACE was recorded during the 6-month follow-up and patients were assigned to MACE and non-MACE subgroups. RESULTS: The presence of symptomatic PAD was significantly correlated with age, diabetes, hsCRP, RBP4 and low adiponectin levels (p < 0.05). After adjustment for age, RBP4 (β = 0.498, p < 0.001), and adiponectin (β = -0.288, p < 0.001) levels remained as independent predictors of PAD presence in the whole study cohort. At baseline, MACE subgroup appeared with higher RBP-4 and hsCRP serum levels than non-MACE subgroup (p < 0.001), but no differences were detected for adiponectin (p = 0.758). Serum RBP4 levels remained independent predictor of MACE (β = 0.455, p < 0.001) after adjustment for traditional cardiovascular risk factors. CONCLUSIONS: High RBP4 and low adiponectin serum levels are independently associated with PAD presence. In addition, RBP4 is an independent predictor of MACE incidence in symptomatic PAD patients.
No takes yet. Share an insight, caveat, or question.
Kadoglou et al. (2021) conducted a cohort in Peripheral artery disease (n=256). Serum RBP4 and adiponectin levels vs. Controls / Non-MACE subgroup was evaluated on Major adverse cardiovascular events (MACE) (β 0.455, p=<0.001). Elevated serum RBP4 levels independently predicted the incidence of major adverse cardiovascular events during a 6-month follow-up in patients with symptomatic peripheral artery disease undergoing endovascular revascularization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: